Annual CFF
$3.44 M
-$10.01 M-74.39%
01 December 2023
Summary:
Plus Therapeutics annual cash flow from financing activities is currently $3.44 million, with the most recent change of -$10.01 million (-74.39%) on 01 December 2023. During the last 3 years, it has risen by +$3.76 million (+1179.94%). PSTV annual CFF is now -94.67% below its all-time high of $64.68 million, reached on 31 December 2010.PSTV Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$0.00
-$6.96 M-100.00%
01 September 2024
Summary:
Plus Therapeutics quarterly cash flow from financing activities is currently $0.00, with the most recent change of -$6.96 million (-100.00%) on 01 September 2024. Over the past year, it has increased by +$529.00 thousand (+100.00%). PSTV quarterly CFF is now -100.00% below its all-time high of $26.84 million, reached on 31 December 2010.PSTV Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$5.66 M
-$2.52 M-30.81%
01 September 2024
Summary:
Plus Therapeutics TTM cash flow from financing activities is currently $5.66 million, with the most recent change of -$2.52 million (-30.81%) on 01 September 2024. Over the past year, it has increased by +$2.21 million (+64.24%). PSTV TTM CFF is now -91.25% below its all-time high of $64.68 million, reached on 31 December 2010.PSTV TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PSTV Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +100.0% | +64.2% |
| 3 y3 years | +1179.9% | -100.0% | -77.1% |
| 5 y5 years | -51.9% | -100.0% | -59.0% |
PSTV Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -83.1% | +1179.9% | -100.0% | +100.0% | -77.1% | +160.0% |
| 5 y | 5 years | -83.1% | +1179.9% | -100.0% | +100.0% | -77.1% | +223.6% |
| alltime | all time | -94.7% | +143.2% | -100.0% | +100.0% | -91.3% | +171.0% |
Plus Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $0.00(-100.0%) | $5.66 M(-30.8%) |
| June 2024 | - | $6.96 M(-997.3%) | $8.18 M(+275.8%) |
| Mar 2024 | - | -$776.00 K(+46.7%) | $2.18 M(-36.8%) |
| Dec 2023 | $3.44 M(-74.4%) | -$529.00 K(-121.0%) | $3.44 M(-15.4%) |
| Sept 2023 | - | $2.52 M(+162.2%) | $4.07 M(-49.0%) |
| June 2023 | - | $961.00 K(+94.9%) | $7.98 M(+20.0%) |
| Mar 2023 | - | $493.00 K(+398.0%) | $6.65 M(-50.5%) |
| Dec 2022 | $13.45 M(-34.1%) | $99.00 K(-98.5%) | $13.45 M(+2.7%) |
| Sept 2022 | - | $6.43 M(-1833.4%) | $13.09 M(+0.4%) |
| June 2022 | - | -$371.00 K(-105.1%) | $13.04 M(-29.6%) |
| Mar 2022 | - | $7.29 M(-2926.4%) | $18.52 M(-9.3%) |
| Dec 2021 | $20.42 M(-6500.0%) | -$258.00 K(-104.0%) | $20.42 M(-17.3%) |
| Sept 2021 | - | $6.37 M(+24.8%) | $24.67 M(+30.0%) |
| June 2021 | - | $5.11 M(-44.4%) | $18.97 M(+113.4%) |
| Mar 2021 | - | $9.19 M(+129.8%) | $8.89 M(-2886.8%) |
| Dec 2020 | -$319.00 K(-102.5%) | $4.00 M(+494.4%) | -$319.00 K(-93.0%) |
| Sept 2020 | - | $673.00 K(-113.5%) | -$4.58 M(-149.9%) |
| June 2020 | - | -$4.97 M(>+9900.0%) | $9.17 M(-14.4%) |
| Mar 2020 | - | -$18.00 K(-93.1%) | $10.72 M(-15.1%) |
| Dec 2019 | $12.63 M(+76.2%) | -$259.00 K(-101.8%) | $12.63 M(-8.6%) |
| Sept 2019 | - | $14.42 M(-521.1%) | $13.81 M(+136.8%) |
| June 2019 | - | -$3.42 M(-281.1%) | $5.83 M(-36.6%) |
| Mar 2019 | - | $1.89 M(+105.1%) | $9.21 M(+28.5%) |
| Dec 2018 | $7.17 M(-57.4%) | $922.00 K(-85.7%) | $7.17 M(-53.5%) |
| Sept 2018 | - | $6.45 M(<-9900.0%) | $15.40 M(+72.5%) |
| June 2018 | - | -$50.00 K(-66.7%) | $8.93 M(-47.5%) |
| Mar 2018 | - | -$150.00 K(-101.6%) | $17.00 M(+1.1%) |
| Dec 2017 | $16.82 M(-4.5%) | $9.16 M(<-9900.0%) | $16.82 M(+80.1%) |
| Sept 2017 | - | -$28.00 K(-100.3%) | $9.34 M(+5.1%) |
| June 2017 | - | $8.02 M(-2494.0%) | $8.89 M(-48.4%) |
| Mar 2017 | - | -$335.00 K(-119.9%) | $17.21 M(-2.3%) |
| Dec 2016 | $17.61 M(-15.3%) | $1.68 M(-452.4%) | $17.61 M(+10.9%) |
| Sept 2016 | - | -$477.00 K(-102.9%) | $15.87 M(-10.2%) |
| June 2016 | - | $16.34 M(>+9900.0%) | $17.67 M(+3.5%) |
| Mar 2016 | - | $62.00 K(-214.8%) | $17.08 M(-17.9%) |
| Dec 2015 | $20.80 M(-32.6%) | -$54.00 K(-104.1%) | $20.80 M(-36.1%) |
| Sept 2015 | - | $1.32 M(-91.6%) | $32.55 M(-4.0%) |
| June 2015 | - | $15.75 M(+316.9%) | $33.90 M(+22.1%) |
| Mar 2015 | - | $3.78 M(-67.7%) | $27.76 M(-10.1%) |
| Dec 2014 | $30.87 M(+48.6%) | $11.70 M(+338.4%) | $30.87 M(-9.6%) |
| Sept 2014 | - | $2.67 M(-72.2%) | $34.16 M(+8.6%) |
| June 2014 | - | $9.61 M(+39.4%) | $31.45 M(+15.1%) |
| Mar 2014 | - | $6.89 M(-54.0%) | $27.34 M(+31.6%) |
| Dec 2013 | $20.77 M(-6.4%) | $14.98 M(<-9900.0%) | $20.77 M(-6.9%) |
| Sept 2013 | - | -$39.00 K(-100.7%) | $22.32 M(-0.0%) |
| June 2013 | - | $5.49 M(+1554.8%) | $22.32 M(+29.0%) |
| Mar 2013 | - | $332.00 K(-98.0%) | $17.31 M(-22.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2012 | $22.19 M(+10.2%) | $16.53 M(<-9900.0%) | $22.19 M(+126.9%) |
| Sept 2012 | - | -$33.00 K(-106.9%) | $9.78 M(-61.3%) |
| June 2012 | - | $477.00 K(-90.9%) | $25.30 M(+2.5%) |
| Mar 2012 | - | $5.22 M(+26.6%) | $24.68 M(+22.6%) |
| Dec 2011 | $20.14 M(-68.9%) | $4.12 M(-73.4%) | $20.14 M(-53.0%) |
| Sept 2011 | - | $15.49 M(<-9900.0%) | $42.86 M(+56.6%) |
| June 2011 | - | -$148.00 K(-122.0%) | $27.38 M(-42.9%) |
| Mar 2011 | - | $674.00 K(-97.5%) | $47.93 M(-25.9%) |
| Dec 2010 | $64.68 M(+166.5%) | $26.84 M(>+9900.0%) | $64.68 M(+47.7%) |
| Sept 2010 | - | $8000.00(-100.0%) | $43.80 M(-10.1%) |
| June 2010 | - | $20.40 M(+17.1%) | $48.72 M(+48.7%) |
| Mar 2010 | - | $17.43 M(+192.3%) | $32.75 M(+34.9%) |
| Dec 2009 | $24.27 M(-30.5%) | $5.96 M(+21.0%) | $24.27 M(-2.5%) |
| Sept 2009 | - | $4.93 M(+11.1%) | $24.90 M(-30.8%) |
| June 2009 | - | $4.44 M(-50.4%) | $35.97 M(-5.3%) |
| Mar 2009 | - | $8.94 M(+35.7%) | $37.99 M(+8.8%) |
| Dec 2008 | $34.93 M(+31.4%) | $6.59 M(-58.8%) | $34.93 M(+21.9%) |
| Sept 2008 | - | $15.99 M(+147.5%) | $28.65 M(+122.4%) |
| June 2008 | - | $6.46 M(+9.8%) | $12.88 M(+2.4%) |
| Mar 2008 | - | $5.88 M(+1761.4%) | $12.58 M(-52.7%) |
| Dec 2007 | $26.58 M(+58.3%) | $316.00 K(+40.4%) | $26.58 M(-0.1%) |
| Sept 2007 | - | $225.00 K(-96.3%) | $26.59 M(-37.6%) |
| June 2007 | - | $6.16 M(-69.0%) | $42.63 M(+17.2%) |
| Mar 2007 | - | $19.88 M(+5922.7%) | $36.37 M(+116.6%) |
| Dec 2006 | $16.79 M(+213.4%) | $330.00 K(-98.0%) | $16.79 M(-12.3%) |
| Sept 2006 | - | $16.27 M(<-9900.0%) | $19.14 M(+579.1%) |
| June 2006 | - | -$102.00 K(-134.8%) | $2.82 M(-52.1%) |
| Mar 2006 | - | $293.00 K(-89.1%) | $5.88 M(+9.8%) |
| Dec 2005 | $5.36 M(-744.6%) | $2.68 M(-5156.6%) | $5.36 M(+119.5%) |
| Sept 2005 | - | -$53.00 K(-101.8%) | $2.44 M(-5.2%) |
| June 2005 | - | $2.96 M(-1371.7%) | $2.58 M(-656.4%) |
| Mar 2005 | - | -$233.00 K(-1.3%) | -$463.00 K(-44.3%) |
| Dec 2004 | -$831.00 K(-16.6%) | -$236.00 K(-387.8%) | -$831.00 K(-61.1%) |
| Sept 2004 | - | $82.00 K(-207.9%) | -$2.13 M(+68.7%) |
| June 2004 | - | -$76.00 K(-87.4%) | -$1.26 M(-4.7%) |
| Mar 2004 | - | -$601.00 K(-60.9%) | -$1.33 M(+33.2%) |
| Dec 2003 | -$997.00 K(-87.5%) | -$1.54 M(-261.8%) | -$997.00 K(-62.4%) |
| Sept 2003 | - | $951.00 K(-784.2%) | -$2.65 M(-50.2%) |
| June 2003 | - | -$139.00 K(-48.5%) | -$5.33 M(-30.4%) |
| Mar 2003 | - | -$270.00 K(-91.6%) | -$7.65 M(-4.1%) |
| Dec 2002 | -$7.97 M(-721.3%) | -$3.20 M(+85.8%) | -$7.97 M(+66.9%) |
| Sept 2002 | - | -$1.72 M(-30.1%) | -$4.78 M(+56.3%) |
| June 2002 | - | -$2.46 M(+315.2%) | -$3.06 M(+415.2%) |
| Mar 2002 | - | -$593.00 K | -$593.00 K |
| Dec 2001 | $1.28 M(-97.3%) | - | - |
| Dec 2000 | $47.44 M(+498.6%) | - | - |
| Dec 1999 | $7.92 M(+331.4%) | - | - |
| Dec 1998 | $1.84 M | - | - |
FAQ
- What is Plus Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Plus Therapeutics?
- What is Plus Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Plus Therapeutics?
- What is Plus Therapeutics quarterly CFF year-on-year change?
- What is Plus Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Plus Therapeutics?
- What is Plus Therapeutics TTM CFF year-on-year change?
What is Plus Therapeutics annual cash flow from financing activities?
The current annual CFF of PSTV is $3.44 M
What is the all time high annual CFF for Plus Therapeutics?
Plus Therapeutics all-time high annual cash flow from financing activities is $64.68 M
What is Plus Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of PSTV is $0.00
What is the all time high quarterly CFF for Plus Therapeutics?
Plus Therapeutics all-time high quarterly cash flow from financing activities is $26.84 M
What is Plus Therapeutics quarterly CFF year-on-year change?
Over the past year, PSTV quarterly cash flow from financing activities has changed by +$529.00 K (+100.00%)
What is Plus Therapeutics TTM cash flow from financing activities?
The current TTM CFF of PSTV is $5.66 M
What is the all time high TTM CFF for Plus Therapeutics?
Plus Therapeutics all-time high TTM cash flow from financing activities is $64.68 M
What is Plus Therapeutics TTM CFF year-on-year change?
Over the past year, PSTV TTM cash flow from financing activities has changed by +$2.21 M (+64.24%)